Preliminary safety and efficacy data from the first-ever trial studying an in vivo genome editing therapy have been presented by Joseph Muenzer, MD, PhD, at the 2019 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism this week in Athens, Greece. Muenzer, a Professor of Pediatric Genetics and Metabolism and a principal investigator of the ongoing CHAMPIONS trial, discussed initial results during the symposium’s Lysosomal Storage Disorders session. Read more >>